Among the therapeutic areas, the oncology segment led the global next-generation antibody therapeutics
market in 2014, with the largest market size, but the autoimmune/inflammatory is expected to see the fastest growth of 46.
CytomX Therapeutics is a biotechnology company focused on revolutionizing the monoclonal antibody field by creating a new generation of highly targeted antibody therapeutics
com/research/wwvgs8/advances_in) has announced the addition of the "Advances in monoclonal antibody therapeutics
" report to their offering.
ALD403 is Alder's calcitonin gene-related peptide (CGRP) inhibiting antibody therapeutic
for treatment of migraine.
a privately held biotherapeutics company focused on the development of best-in-class bi-specific antibody therapeutics
and multi-valent protein therapeutics, today announced the completion of a common share offering totaling $11.
New analysis from Frost & Sullivan, Advances in Monoclonal Antibody Therapeutics
Currently there is a significant research effort to develop monoclonal antibody therapeutics
to treat a range of diseases including cancer, inflammatory and autoimmune disorders," continued Dr.
RuiYi is focused on the discovery and development of novel antibody therapeutics
with upsized potential that represent (1) first in class antibody therapeutics
to GPCR targets validated with small molecules yet never successfully drugged and (2) best in class antibody therapeutics
to validated targets for unique markets with significant medical need.
Vancouver, Canada, a privately-held biomedical company, have announced a collaboration through which the two companies expect to utilize Medarex's HuMAb-Mouse technology to develop fully human antibody therapeutics
for central nervous system disorders.
com) announces updates to their Antibody Therapeutics
com/research/9n5sj5/bispecific) has announced the addition of the "Bispecific Antibody Therapeutics
Market (2nd Edition), 2014 - 2024" report to their offering.
have formed an alliance to develop fully human antibody therapeutics
Our platform provides key competitive advantages in antibody optimization and discovery, enabling us to build a pipeline of antibody therapeutics
with best-in-class potential.
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, achieved the first research milestone in its antibody therapeutics
alliance with MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX), announced in February 2013.
The novel discovery format is analogous to a combinatorial chemistry library and enables direct cell based screening, opening novel targets to antibody therapeutics
like G-protein coupled receptors or ion channels.